References
- American Thoracic SocietyGuidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumoniaAm J Respir Crit Care Med2005171438841615699079
- KollefMHShorrATabakYPGuptaVLiuLZJohannesRSEpidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumoniaChest200512863854386216354854
- MastertonRGGallowayAFrenchGGuidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial ChemotherapyJ Antimicrob Chemother200862153418445577
- ChastreJFagonJYVentilator-associated pneumoniaAm J Respir Crit Care Med2002165786790311934711
- DavisJFinleyEFocus on Infection Prevention. The breadth of hospital-acquired pneumonia: nonventilated versus ventilated patients in PennsylvaniaPennsylvania Patient Safety Advisory20129399106
- EsperattiMFerrerMTheessenANosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patientsAm J Respir Crit Care Med2010182121533153920693381
- YangYSLeeYTHuangTWAcinetobacter baumannii nosocomial pneumonia: is the outcome more favorable in non-ventilated than ventilated patients?BMC Infect Dis20131314223509931
- BousbiaSPapazianLSauxPRepertoire of intensive care unit pneumonia microbiotaPLoS One201272e3248622389704
- WeberDJRutalaWASickbert-BennettEESamsaGPBrownVNiedermanMSMicrobiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumoniaInfect Control Hosp Epidemiol200728782583117564985
- BhavnaniSMRubinoCMHammelJPPharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineAntimicrob Agents Chemother20125621065107222143524
- SopenaNSabriàMMulticenter study of hospital-acquired pneumonia in non-ICU patientsChest2005127121321915653986
- LundeCSHartouniSRJancJWMammenMHumphreyPPBentonBMTelavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid IIAntimicrob Agents Chemother20095383375338319470513
- LundeCSRexerCHHartouniSRAxtSBentonBMFluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureusAntimicrob Agents Chemother20105452198220020176907
- HigginsDLChangRDebabovDVTelavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20054931127113415728913
- GotfriedMHShawJPBentonBMIntrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibioticsAntimicrob Agents Chemother2008521929717923490
- LodiseTPJrGotfriedMBarriereSDrusanoGLTelavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulationAntimicrob Agents Chemother20085272300230418426898
- RubinsteinELalaniTCoreyGRTelavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogensClin Infect Dis2011521314021148517
- CLSIMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Seventh EditionM7-A7Wayne, PACLSI2006 Available from: http://isoforlab.com/phocadownload/csli/M7-A7.pdfAccessed April 3, 2014
- SaravolatzLDSteinGEJohnsonLBTelavancin: a novel lipoglycopeptideClin Infect Dis200949121908191419911938